Detalles de la búsqueda
1.
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.
J Allergy Clin Immunol
; 152(1): 155-166.e9, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37003475
2.
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy.
J Allergy Clin Immunol
; 149(6): 2166-2170.e1, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35026206
3.
Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.
Allergy
; 77(8): 2534-2548, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35266148
4.
Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Allergy
; 77(3): 991-1003, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34320250
5.
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
Ann Allergy Asthma Immunol
; 129(6): 758-768.e4, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973655
6.
Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis.
J Allergy Clin Immunol
; 147(6): 2249-2262.e7, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33571537
7.
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
Gastroenterology
; 152(4): 787-798.e2, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27864127
8.
Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.
Am J Gastroenterol
; 113(3): 339-347, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29460921
9.
Oral Immunotherapy for Peanut Allergy.
N Engl J Med
; 380(7): 691-692, 2019 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30763186
10.
A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.
Value Health
; 20(4): 637-643, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28408006
11.
Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
Gastroenterology
; 146(7): 1649-58, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24583059
12.
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.
Dig Dis Sci
; 57(2): 440-50, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21948339
13.
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
Lancet Child Adolesc Health
; 4(10): 728-739, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702315
14.
Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.
GastroHep
; 1(6): 293-301, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32313451
15.
A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.
Cell Mol Gastroenterol Hepatol
; 4(1): 1-17, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28508029
16.
Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy.
J Allergy Clin Immunol Pract
; 9(12): 4496-4501, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34389504
17.
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Circulation
; 108(11): 1310-5, 2003 Sep 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-12939212
18.
Assessing Quality of Life in Patients with Common Variable Immunodeficiency: Why It Matters.
J Allergy Clin Immunol Pract
; 4(6): 1180-1181, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27836063
19.
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
J Thorac Oncol
; 6(2): 384-6, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21252718
20.
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Clin Cancer Res
; 16(7): 2167-75, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20233886